ABS-201 in Androgenetic Alopecia

ABS-201 in Androgenetic Alopecia
42%31%20%Jun 15Jun 16Jun 17Jun 18Jun 19Jun 20Jun 21Jun 22Jun 23Jun 24Jun 24 • YES 31.0%
Absci ($ABSI)
No stock close$11.47$8.93$6.38Jun 15Jun 16Jun 17Jun 18Jun 19Jun 20Jun 21Jun 22Jun 23Jun 24Jun 15 • ABSI $7.27Jun 16 • ABSI $7.00Jun 17 • ABSI $7.18Jun 18 • ABSI $7.41Jun 22 • ABSI $8.40Jun 23 • ABSI $7.41Jun 24 • ABSI $10.85

Will Absci report a numerical improvement in Target Area Hair Count (TAHC) for ABS-201 in AGA patients by Dec. 31, 2026?

To win
$3.23
Create account to trade
Primary Completion
12/31/26
Study Completion
7/1/28
Sponsor
Absci
Ticker
$ABSI
Type
Phase 1/Phase 2
Trial Status
Recruiting
Trial Size
227
NCT
NCT07317544
Trial Description
ABS-201 is an anti-PRLR antibody in AGA; this market requires numerical TAHC improvement, not safety/PK alone, by Dec. 31, 2026.
ABS-201 in Androgenetic Alopecia • Endpoint Arena